For every day MAX from OptiBac Probiotics

‘For every day MAX’ offers Quality, not just Quantity; these 3 strains have been proven to reach the gut alive, surviving the passage through stomach acid and bile salts; each one has been extensively researched in a variety of health conditions, including IBS, digestive comfort and immunity, to name a few. With an estimated collection of 90+ clinical trials on these strains, this is the most researched 50 billion live cultures supplement on the market, offering a high quality option to those seeking a high billions product.

Clinical trials on B. lactis HN019

Clinically shown to support overall gut health

Gastrointestinal symptoms

In one trial 88 participants, with confirmed functional gastrointestinal symptoms, were given either placebo or probiotic B. lactis HN019 in either a low dose (1.8 billion) or a high dose (17.5 billion)

They wanted to see if the frequency of gut symptoms experienced were affected by the probiotic and whether the dose of B. lactis HN019 was a significant factor.


Increase in lactobacillus count graph
Reduction of gastrointestinal symptoms graph


They found that while both probiotic groups had a positive impact on symptoms, the high dose had a more significant impact on a greater number of symptoms.

8/9 of the whole gut symptoms improved significantly in the high dose group, while only 2/9 improved in the placebo group.

We often think of transit time in terms of the colon and constipation, however whole gut transit time (WGTT) takes the motility of the whole intestine into consideration. Slow WGTT can be associated with other health complications, such as gallstones and small intestinal overgrowth (SIBO).

Ingestion of radiopaque markers and intermittent x-rays identified the transit time at different stages of digestion; those who started the study with slow WGTT experienced vast improvements when taking B. lactis HN019. Result showed the high dose group achieved more significant improvements overall.

Reassuringly, those who started out with normal WGTT did not see a significant change, therefore identifying that B. lactis HN019 will not speed up transit times in those who do not need to.

Waller, P. A. et al (2011) Dose-response effect of Bifidobacterium lactis HN019 on whole gut transit time and functional gastrointestinal symptoms in adults. Scandinavian Journal of Gastroenterology. 1057–1064

Prebiotic effects of probiotic B. lactis HN019

In one clinical trial, 30 participants were split into 3 groups: Prebiotic (2.4g GOS), probiotic (30 billion B. lactis HN019) and placebo.

They compared the effect each intervention had on the indigenous gut microbiota:

The study shows supplementation with B. lactis HN019 (a Bifidobacterium strain) increases levels of resident Lactobacillus in the gut.

Increase in Lactobacillus count graph

The probiotic group showed similar results (increases in lactobacillus) to the GOS group

This means that those who are sensitive to prebiotics can still experience proliferation of their gut bacteria, when taking ‘For every day MAX’

Gopal, P. K. et al (2003) Effects of the consumption of Bifidobacterium lactis HN019 (DR10TM) and galacto-oligosaccharides on the microflora of the gastrointestinal tract in human subjects. Nutrition Research. 23 1313-1328

Miller, L.E. et al (2016) Contemporary meta-analysis of short-term probiotic consumption on gastrointestinal transit. World journal of gastroenterology. 22 (21) 5122 – 5131

B. lactis HN019 shows Anti-inflammatory activity

In one of the very few studies on the topic, B. lactis HN019 was found to improve associated measurements of metabolic syndrome (MetS), a condition characterised by increased risk of obesity, systemic inflammation and dyslipidaemia.

51 participants with MetS were split into two groups; Probiotic B. lactis HN019 or placebo for 45 days. Anthropometric measurements were taken at the start and end of the study; showing significant reduction of Body Mass Index (BMI), blood lipids and pro-inflammatory markers TNF-α and IL-6 compared to baseline and placebo group values.

The author concluded that regular consumption of B. lactis HN019 may contribute to the reduction of some pro-inflammatory markers and obesity, among other parameters of MetS.

Bernini, L. J. et al (2016) Beneficial effects of Bifidobacterium lactis on lipid profile and cytokines in patients with metabolic syndrome: A randomized trial. Effects of probiotics on metabolic syndrome. Nutrition 32(6):716-9

Ahmed, M. et al (2007) Impact of consumption of different levels of Bifidobacterium lactis HN019 on the intestinal microflora of elderly human subjects. J Nutr. 11: 26-31.

Arunachalam K, et al (2000) Enhancement of natural immune function by dietary consumption of Bifidobacterium lactis (HN019). Eur J Clin Nutr. 54: 263-267.

Chiang, B. L. et al (2000) Enhancing immunity by dietary consumption of a probiotic lactic acid bacterium (Bifidobacterium lactis HN019): optimization and definition of cellular immune responses. Eur J Clin Nutr. 54: 849-855.

Understanding clinical trials on IBS:

We often see reports of IBS focussed trials being interpreted as inconclusive or insignificant, however the microbiology institutions often express the difficulty in measuring IBS results as the term encompasses a wide range of symptoms, all of which are subjective and self-reported. Everyone seems to experience their IBS differently and each have a different set of symptoms.

Clinical trials have helped us to identify how specific strains may benefit particular symptoms of IBS, so that we may use the research to select the most appropriate live cultures supplement for different needs. This continues to support our message that a ‘one size fits all’ approach is not good enough and explains why we have so many products within the OptiBac range.

Clinical trials on L. acidophilus NCFM®

Study shows L. acidophilus NCFM® reduces abdominal pain & bloating

One such study investigated the beneficial activity of L. acidophilus NCFM® on 391 subjects with IBS. Participants were given either 1 billion or 10 billion L. acidophilus NCFM® per day, for a period of 12 weeks, or a placebo.

Percentage of reduction graph

Both groups taking the live cultures were shown specifically to have a reduction in gut pain, with the higher dose offering a slightly improved score.

L. acidophilus NCFM® at 10 billion CFU reduced discomfort in the gut by over 30% from the baseline; this was 10% more than the placebo group - a statistically significant result.

This trial is particularly relevant for sufferers of IBS who frequently experience spasms, cramps and abdominal pain.

Lyra, A. et al (2016) Irritable bowel syndrome symptom severity improves equally with probiotic and placebo. World journal of gastroenterology. 22 (48)

L. acidophilus NCFM® shown to reduce discomfort in the gut

The above trial is one of many to show L. acidophilus NCFM® has the ability to reduce gut related pain in IBS sufferers. This study sought to find a ‘mechanism of action’, to understand how this incredible strain may be exerting this benefit.

pre-patient fold increase

In the gut we have ‘pain receptors’ (MOR receptors) which are responsible for receiving information from inside the intestines and communicating it to the brain.

When MOR receptors are stimulated, pain sensation in the intestines is reduced.

In a clinical study, intestinal tissue samples showed L. acidophilus NCFM® is able to reduce pain in the gut by increasing MOR receptor expression 40-fold, when compared to pre-study tissue samples

Ringel-Kulka (2014)Lactobacillus acidophilus NCFM affects colonic mucosal opioid receptor expression in patients with functional abdominal pain - a randomised clinical study. Ailment. Pharmacol. Ther. 40, 2. 200-7

Immunomodulation via dendritic cell communication

Dendritic cells (DCs) are antigen presenting cells which sample antigens (e.g. pathogenic bacteria) and then use the information received to influence the relative immune response; they’re in regular contact with intestinal bacteria and act as a bridge between the innate and adaptive immune systems, they are responsible for maintaining mucosal immunity and identifying the difference between indigenous bacteria and pathogens.

A study has shown that L. acidophilus NCFM® is able to bind to DC receptors and beneficially modulate its immunological activity.

Konstantinov, S. R et al (2008) S layer protein A of Lactobacillus acidophilus NCFM regulates immature dendritic cell and T cell functions. PNAS. 105 (49): 19474-19479

L. acidophilus NCFM® tested against harmful enzyme activity

Some pathogenic bacteria produce enzymes, such as azoreductase, nitroreductase and β-glucoronidase, which have the potential to induce lesions in the colon (Aberrant crypt foci- ACF) known markers for carcinogenesis.

In a human intervention trial investigating the effect of L. acidophilus NCFM® on enzyme activity, they found this strain caused a significant decline in the specific activity of the three enzymes in all subjects after 10 d of consumption. The wash out period highlighted the need for continuous intake for results to be maintained. This does not conclude that L. acidophilus NCFM® will treat or prevent colon cancer, but may reduce the associated enzymatic activity.

Goldin, B.R. and Gorbach, S.L. (1984). The effect of milk and Lactobacillus feeding on human intestinal bacterial enzyme activity. American Journal of Clinical Nutrition. 39:756-761.

Fotiadis, C. I. et al (2008) Role of probiotics, prebiotics and synbiotics in chemoprevention for colorectal cancer. World J Gastroenterol. 14(42): 6453-6457

L. acidophilus NCFM® is one of few strains showing strong oxalate degradation capacity:

Turroni, S. et al (2007) Oxalate consumption by lactobacilli: evaluation of oxalyl-CoA decarboxylase and formyl-CoA transferase activity in Lactobacillus acidophilus. Journal of applied Microbiology. 1364 -5072

Clinical trials on B. lactis HN019 & L. acidophilus NCFM®

In a clinical study looking at colonic transit time, a symbiotic (L. acidophilus NCFM® & B. lactis HN019) was compared to placebo. The treatment group showed significantly improved Agachan scores (constipation assessment system) and an increase in the average number of daily bowel movements, compared to the placebo group.

Magro, D.O. et al (2014) Effect of yoghurt containing polydextrose, L. acidophilus NCFM and B. lactis HN019: a randomized, double-blind, controlled study in chronic constipation . Nutrition Journal. 13:75

Clinical trials on B. lactis Bl-04

In a gold standard clinical trial, the effects of probiotic B. lactis Bl-04 on the risk of common cold & flu was studied in 465 healthy, active participants.

Participants who took B. lactis Bl-04 showed a significant 27% reduced risk of developing an upper respiratory tract infection compared to placebo.

Furthermore, those in the B. lactis Bl-04 probiotic group who did experience a cold or flu, had a 28% reduced risk of recurrence of the infection

West, N. P. et al (2013) Probiotic supplementation for respiratory and gastrointestinal illness symptoms in healthy, physically active individuals. Clinical Nutrition. 33, 4. pp. 581-7

Clinical trials on L. acidophilus NCFM® & B. lactis Bl-04

Ouewhand, AC et al. (2009) Specific probiotics alleviate allergic rhinitis during the birch pollen season. World Journal of Gastronenterol; Vol. 15, pp. 3261 – 3268